Thursday, February 14, 2019

The Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder


Substance use disorder is characterised by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues.

In turn, a number of cannabinoid drugs (e.g. rimonobant, nabiximol) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol (CBD), a nonpsychoactive phytocannabinoid found in the cannabis plant, has also been proposed as a potentially effective treatment for the management of substance use disorder. Animal and human studies suggest that these cannabinoids have the potential to reduce craving and relapse in abstinent substance users, by impairing reconsolidation of drug-reward memory, salience of drug cues, and inhibiting the reward-facilitating effect of drugs. Such functions likely arise through the targeting of the endocannabinoid and serotoninergic systems, although the exact mechanism is yet to be elucidated. 

This article seeks to review the role of the endocannabinoid system in substance use disorder and the proposed pharmacological action supporting cannabinoid drugs’ therapeutic potential in addictions, with a focus on CBD. Subsequently, this article will evaluate the underlying evidence for CBD as a potential treatment for substance use disorder, across a range of substances including nicotine, alcohol, psychostimulants, opioids, and cannabis. 

While early research supports CBD’s promise, further investigation and validation of CBD’s efficacy, across preclinical and clinical trials will be necessary.

Source: https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00063/abstract
Keywords: endocannabinoid system, ECS, substance use disorder, treatment efficacy, Cannabidiol, cbd, Addiction
Received: 30 Nov 2018; Accepted: 28 Jan 2019. 
Edited by:
Alexander M. Baldacchino, University of St Andrews, United Kingdom
Reviewed by:
Aviv M. Weinstein, Ariel University, Israel 
Carla Cannizzaro, University of Palermo, Italy  

No comments:

Post a Comment